Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$105.5MCash, Jun 2026
5moCash Runway (est.)
+31%Share Count, 1 Year
Follow RGNX by emailGet an email when RGNX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RGNX, unsubscribe in one click. Privacy
📣 What RGNX Says Is Next
Q4 2026 · “REGENXBIO expects to announce topline data with AbbVie from the ATMOSPHERE ® and ASCENT ® pivotal trials of sura-vec using subretinal delivery in Q4 2026.”
Company press release, Aug 6, 2026 · SEC filing
1H 2027 · “REGENXBIO expects to initiate AFFINITY ® RISE, a new, ex-U.S. randomized, placebo-controlled study to support RGX-202 global regulatory submissions, in 1H 2027.”
Company press release, Aug 6, 2026 · SEC filing
Q4 2027 · “In addition to extending the company’s expected cash runway into Q4 2027, proceeds will support the initiation of the planned AFFINITY ® RISE ex-U.S. randomized-controlled trial in 1H 2027 to support global regulatory submissions for RGX-202.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
RGNX reported $105.5M in cash and short-term investments (as of Jun 30, 2026) and used about $69.8M/quarter in operations, an estimated runway of 4.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:69 · High
Cash runway 4 months +40
ATM program on file since Feb 2026 +15
Shelf registration (S-3, Nov 2025) +10
Share count +31% in a year +14
Raised after last reported balance sheet (Jul 2026) -10
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RGNX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.